These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 8769191

  • 1. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C, Melchor JL, Miranda ME, Bartolano C.
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract] [Full Text] [Related]

  • 2. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C, Melchor JL.
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract] [Full Text] [Related]

  • 3. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H, Asmundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K.
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B, Korn A.
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of Neoral in transplant recipients.
    Feutren G, Wong R, Jin J, Niese D, Mellein B.
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract] [Full Text] [Related]

  • 9. A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients.
    Rosental R, Bicans J, Berzina R, Zezina L.
    Transplant Proc; 1995 Dec; 27(6):3436-7. PubMed ID: 8540038
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin in a porcine renal transplant model.
    Almond PS, Moss A, Nakhleh R, Melin M, Chen S, Salazar A, Shirabe K, Matas A.
    Transplant Proc; 1993 Feb 27; 25(1 Pt 1):716. PubMed ID: 8438452
    [No Abstract] [Full Text] [Related]

  • 16. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU, Grosso S, de Boccardo G, Vásquez MC, Schiavelli RO, Sabbatiello RR, Casadei DH, Rial MC, Jost LJ, Túrin MD, Agost Carreño C A, Maggiora EC, Gadea MM.
    Transplant Proc; 1996 Dec 27; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G, Bunke CM, Choc MG, Hricik DE, Jin JH, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL.
    Transplant Proc; 1996 Aug 27; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract] [Full Text] [Related]

  • 18. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
    Montagnino G, Tarantino A, Aroldi A, Banfi G, Cesana B, Ponticelli C.
    Transplant Proc; 1994 Oct 27; 26(5):2634-6. PubMed ID: 7940821
    [No Abstract] [Full Text] [Related]

  • 19. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients.
    Cheung CY, Wong KM, Chan HW, Liu YL, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Li CS.
    Transpl Int; 2006 Aug 27; 19(8):657-66. PubMed ID: 16827683
    [Abstract] [Full Text] [Related]

  • 20. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A, Shekhar C, Heer M, Minz M.
    Transplant Proc; 2006 Sep 27; 38(7):2051-3. PubMed ID: 16979996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.